Women's Hormone Health

Is Hormone Therapy Safe for Women? What Has Changed Since the WHI

For most healthy women under 60, or within 10 years of their last period, the benefits of hormone therapy for menopause symptoms outweigh the risks. That conclusion took twenty years to recover from how the original WHI results were reported.

A woman in her fifties in conversation with a clinician - Aevum Restorative Wellness, Houston

Key takeaways

  • The 2002 Women's Health Initiative results caused hormone therapy use to collapse, but the trial's participants were on average 63 years old, older than most women who start treatment for symptoms.
  • In absolute terms, the breast cancer increase seen with combined estrogen and progestin in the WHI was about 8 additional cases per 10,000 women per year.
  • After 18 years of follow-up, women who took hormone therapy in the WHI had no higher risk of death from any cause, heart disease or cancer than those who took placebo.
  • Professional guidance holds that for women under 60 or within 10 years of menopause without contraindications, benefits generally outweigh risks for bothersome hot flashes and preventing bone loss.
  • In 2026 the FDA removed boxed-warning language about heart disease, breast cancer and dementia from menopausal hormone therapy labels. The risks remain listed in the label, and hormone therapy is still not right for everyone.

Many women in their forties and fifties grew up hearing that hormone therapy causes breast cancer and heart attacks. Some were taken off it abruptly in 2002. Others were never offered it at all. If that describes you, it is worth knowing how the evidence has been reinterpreted since.

What the Women's Health Initiative found, and how it was heard

The WHI was a large set of trials funded by the National Institutes of Health. In 2002, its trial of combined estrogen and progestin was stopped early after showing small increases in breast cancer, heart disease, stroke and blood clots, and reductions in fractures and colorectal cancer.

The findings were reported mostly as relative risks, and the public heard "hormones cause breast cancer." In absolute terms, the breast cancer increase was about 8 additional cases per 10,000 women per year of use. That is real and worth discussing. It is also much smaller than the headlines implied.

There was a second problem. The average participant was 63, and many were more than a decade past menopause. The trial was designed to test long-term prevention in older women, not symptom treatment in women in their late forties and early fifties.

What the longer follow-up showed

In 2017, WHI investigators reported 18 years of cumulative follow-up across both hormone trials, covering more than 27,000 women. Women assigned to hormone therapy had no higher risk of death from any cause, from cardiovascular disease, or from cancer than women assigned to placebo.

The analyses by age also pointed in the same direction as later research: the balance of risk and benefit looks considerably better when therapy starts closer to menopause.

What current guidance says

The Menopause Society's 2022 position statement, endorsed by more than 20 international organizations, summarizes the current view:

  • For women younger than 60, or within 10 years of menopause onset, without contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes and night sweats and for preventing bone loss.
  • For women who start more than 10 years after menopause or after 60, the balance is less favorable, because the absolute risks of heart disease, stroke, blood clots and dementia are higher.
  • Risk depends on the type of hormone, the dose, how long it is used, the route, and whether a progestogen is needed. Estrogen through the skin, as a patch or gel, carries a lower risk of blood clots than estrogen by mouth.

What the FDA changed in 2025 and 2026

On November 10, 2025, the FDA announced it would remove the boxed-warning language about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products. It approved the first updated labels in February 2026.

Two things did not change. Estrogen-only products still carry a boxed warning about endometrial cancer, which is why women who still have a uterus take a progestogen alongside estrogen. And information on heart disease and breast cancer remains in the label, outside the boxed warning. The change reflects better context for the risk, not the absence of risk.

Who should not take hormone therapy, or needs a closer look

Some situations rule hormone therapy out. Others change which hormone, dose or route makes sense. They include:

  • A personal history of breast, uterine or other hormone-sensitive cancer
  • A history of blood clots, stroke or certain heart conditions
  • Unexplained vaginal bleeding that has not been evaluated
  • Active liver disease
  • Pregnancy or possible pregnancy

This is why an evaluation comes before any prescription.

How we approach this at Aevum

Your evaluation covers your symptoms, menstrual and menopause history, personal and family history, blood pressure and individual risk factors. When hormone therapy is appropriate, most plans start with an adjustable route, such as a patch or gel, so the dose can be refined. Pellets are considered case by case, because once placed their dose cannot be changed. Sometimes the right answer is a non-hormonal treatment, or no treatment at all.

The short version

Hormone therapy is not risk-free, and it is not right for every woman. For most healthy women with bothersome symptoms who are under 60 or within 10 years of menopause, current evidence and guidance agree that the benefits outweigh the risks. The fear many women still carry comes largely from how one older-age trial was reported in 2002.

Frequently asked questions

Does hormone therapy cause breast cancer?

Combined estrogen and progestin was associated with a small increase in breast cancer in the WHI, about 8 additional cases per 10,000 women per year. Your personal and family history shape what that means for you, and it is part of every evaluation.

Is it too late to start hormone therapy after 60?

Not automatically, but the balance of benefit and risk is less favorable for women who start after 60 or more than 10 years after menopause. It needs a more careful individual assessment.

Did the FDA say hormone therapy is safe?

The FDA removed certain boxed-warning language and updated labels to reflect timing. The risks remain described in the label, and the decision is still an individual one.

Are patches safer than pills?

Estrogen through the skin carries a lower risk of blood clots than estrogen by mouth, according to current guidance. Route is chosen based on your individual risk factors.

How long can I stay on hormone therapy?

There is no fixed cutoff. Current guidance does not require routinely stopping at 60 or 65, but the decision should be reviewed periodically with your clinician.

References

  1. Writing Group for the Women's Health Initiative Investigators (Rossouw JE, et al). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321
  2. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. doi:10.1001/jama.2017.11217
  3. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
  4. US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. February 2026. fda.gov
Xinwei Liu

Xinwei Liu

Medical Director

Dr. Xinwei Liu is the Medical Director at Aevum Restorative Wellness. He is board-certified in Emergency Medicine, completed residency at Kaiser Permanente San Diego, and earned his medical degree at the University of Central Florida.

Read full profile

Medically reviewed

Xinwei Liu

MD

October 15, 2026

November 16, 2026

This article is for general education and is not medical advice. Individual results vary. Speak with a licensed clinician about your own situation.

Next step

Lab-guided care starts with a conversation, not a product.

Explore hormone therapy for women in HoustonBook a Consultation

Aevum Restorative Wellness

1224 Houston Avenue, Suite 101, Houston, TX 77007

713-280-1551

care@aevumrestorative.com

Monday to Friday, 10am to 7pm; Saturday and Sunday, 9am to 5pm